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ABSTRACT
Malaria represents a serious public health problem, presenting with high rates of 
incidence, morbidity and mortality in tropical and subtropical regions of the world. According 
to the World Health Organization, in 2018 there were 228 million cases and 405 thousand 
deaths caused by this disease in the world, affecting mainly children and pregnant women 
in Africa. Despite the programs carried out to control this disease, drug resistance and 
invertebrate vector resistance to insecticides have generated difficulties. An efficient vaccine 
against malaria would be a strategy with a high impact on the eradication and control of this 
disease. Researches aimed at developing vaccines have focused on antigens of high importance 
for the survival of the parasite such as the Circumsporozoite Surface Protein, involved in 
the pre-erythrocytic cycle during parasites invasion in hepatocytes. Currently, RTS’S is the 
most promising vaccine for malaria and was constructed using CSP; its performance was 
evaluated using two types of adjuvants: AS01 and AS02. The purpose of this review was to 
provide a bibliographic survey of historical researches that led to the development of RTS’S 
and its performance analysis over the decade. The search for new adjuvants to be associated 
with this antigen seems to be a way to obtain higher percentages of protection for a future 
malaria vaccine.
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INTRODUCTION 
Malaria represents a serious public health problem; it has high rates of incidence, 
morbidity and mortality in tropical and subtropical regions of the world. Despite 
efforts made with measures to control and prevent the disease, in 2018, 228 million 
cases and 405 thousand deaths were registered worldwide. Plasmodium falciparum 
was responsible for 99.7% of registered cases of malaria in African regions, as well 
as most cases in Southeast Asia (50%), Eastern Mediterranean (71%) and Western 
Pacific (65%)1. Thus, research has been carried out aiming to obtain an accessible, 
safe and efficient vaccine against the parasite, for a long-term control and possible 
eradication of malaria. 
The RTS’S/ AS01 vaccine was designed for the pre-erythrocytic stage of 
P. falciparum, to activate the immune system against the parasite, as soon as it 
enters the human bloodstream, preventing the sporozoites from invading human 
hepatocytes, eliminating infected hepatocytes or impairing the development of 
Plasmodium, making it impossible for the parasite to invade red blood cells2. 
This vaccine uses part of the central repeat domain and the C-terminal region 
of the P. falciparum Circumsporozoite Surface Protein (CSP), also presenting 
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T-cell epitopes coupled to the hepatitis B HBsAg surface 
antigen3,4.
Currently, the RTS’S/ AS01 vaccine is known 
commercially as MosquirixTM, and is produced by 
GlaxoSmithKline Biologicals (GSK SA, United Kingdom). 
This vaccine received a favorable decision from the 
European Medicine Agency (EMA) in July 2015, with 
approval of its quality, safety and effectiveness considering 
benefits and risks5. It is important to highlight that RTS’S/ 
AS01 has also received authorization from the World Health 
Organization (WHO) to carry out pilot tests in the Malaria 
Vaccine Implementation Program (MVIP) and is being 
currently tested in children and pregnant women living in 
endemic African countries, mainly in Sub-Saharan Africa6. 
In the three African countries (Ghana, Kenya and 
Malawi) selected for the pilot tests, the vaccine follows 
the Expanded Program on Immunization (EPI) distribution 
regime, which consists of four doses. In Malawi, the vaccine 
is offered for the first time at 5 months of age, while in 
Ghana and Kenya, the vaccine is offered at 6 months of age, 
with the first three doses delivered at approximately monthly 
intervals and the fourth dose close to 2 years of age7. 
The malaria vaccine is also supported by different 
WHO partner institutions, that are working to validate 
its effectiveness and distribution in pilot immunization 
programs. PATH’s Malaria Vaccine Initiative (MVI) 
provides technical support and project management for 
the program, and Gavi - The Vaccine Alliance, is an 
international organization that brings together the public 
and private sectors with the common goal of creating equal 
access to new and underused vaccines for children living 
in the poorest world countries6.
This vaccine was 50% effective in children of up to one 
year, while in adults, for six months8. However, there is 
still a need to enhance the RTS’S vaccine to obtain better 
immune responses to recombinant antigens, so that different 
formulations have been developed and tested, using new 
adjuvants that are linked to immunomodulators, adapted to 
the antigen and the population that will receive it. Adjuvants 
can activate the entire immune system, enhancing the 
vaccine’s adaptive response9.
RTS’S/ AS02 vaccine is still in phase IIb clinical 
trial and uses the adjuvant AS02. The adjuvant AS01 
(formulated in liposomes) and AS02 (formulated in oil-
in-water emulsion), consist of the following compounds: 
Monophosphoryl lipid A (MPL), which functions as 
an agonist of the TLR4 receptor, activating T-helper 
lymphocytes 1 (Th1) to produce INF-γ, IL-2 and TNF-α 
cytokines, that are related to phagocytosis-mediated 
defense against intracellular infectious agents; and Quillaja 
saponaria Molina, fraction 21 (QS21), that initiates the 
activation of dendritic cells to induce immune responses 
mediated by T cells9,10. 
Thus, this article aimed to present a brief history of the 
findings that led to the development of the malaria vaccine 
using the CSP protein as a target antigen, for the production 
of the RTS’S/ AS01 vaccine and what are the latest findings 
on its effectiveness.
Brief historical survey of malaria vaccine development
Since the 1920s, adjuvants have been developed and 
perfected to increase the immune response against specific 
antigens in order to improve the efficiency of vaccines in 
general. Ramon et al.11, in 1926, demonstrated that adding 
substances such as agar, metal salts, oil, lecithin or saponin 
to the vaccine would artificially increase the levels of tetanus 
and diphtheria antitoxins.
Later in 1931, Glenny et al.12 tested rabbits and guinea 
pigs with the bacterium Corynebacterium diphtheriae, 
which causes diphtheria. In this study, aluminum hydroxide 
(Alum) was used for the first time as an adjuvant, and later 
it would be used in more modern formulations of a vaccine 
against Malaria. However, for certain applications, alum 
salts proved to be of limited use due to their inability to 
stimulate cell-mediated immunity with greater specificity, 
local reactions and production of IgE antibodies13. For this 
reason, it was necessary to develop new and more effective 
adjuvants for malaria vaccines. 
In 1945, Jules Freud et al.14 carried out the first malaria 
vaccine tests. These products were used to immunize 
ducks injected with inactive P. lophurae in association 
with formalin (a substance similar to lanolin), paraffin oil 
and Koch’s bacillus. This organization became known as 
Freund’s Adjuvant. Immunized ducks had a good protection 
against P. lophurae infection, but the vaccine showed some 
adjuvant-induced reactions. Still, in that same year, the 
group studied, but this time using P. knowlesi to inoculate 
Rhesus monkeys. The results obtained were similar to the 
previous ones14.
In 1967, mice were immunized with P. berghei sporozoites 
attenuated by X-radiation through studies carried out at the 
New York University by Ruth Nussenzweig et al.15. The 
results showed that when these animals were challenged with 
non-irradiated sporozoites, there was a decreased infectivity 
of sporozoites to infect hepatocytes. Later, the same result 
was observed in non-human primates16.
Based on the Nussenzweig’s experiment, in 1971, at the 
Walter Reed Military Medical Center, Clyde et al.17 carried 
out the first tests on humans. The study was conducted 
in six adult male volunteers through mosquito bites with 
X-radiation attenuated sporozoites (P. falciparum, P. vivax, 
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and both species), and it was observed that the volunteers 
had low-level parasitemia. Then, a new study was proposed 
with these same volunteers, using the same methodology, 
whose number and degree of infection was sufficient to 
induce the disease in all volunteers who had participated in 
previous tests conducted by Clyde et al.17. As expected, all 
unvaccinated volunteers developed malaria. However, only 
one of the six immunized volunteers obtained protection 
against the disease.
The advent of the monoclonal antibody technology has 
allowed advances in the identification of possible vaccine 
candidates for the parasite in the pre-erythrocytic stage, 
through the presentation of one or more antigens of this 
protozoan, instead of using the entire parasite18,19 (Figure 1).
These advances have led to the principle of discarding 
vaccines based on attenuated sporozoites in humans. The 
concentration of these studies, directed at the protective 
response induced using attenuated sporozoites, led to the 
identification of the circumsporozoite protein (CSP).
CSP antigen: a vaccine candidate
Among the main vaccine antigens, CSP has stood out, 
both for being present in all species of Plasmodium, and 
for the large amount present on the surface of the parasite, 
playing a fundamental role in the invasion of parasites 
into hepatocytes20. It has high immunogenicity in human 
hosts, primates, rodents, and has similar structural and 
immunological characteristics. For these reasons, CSP was 
the first protein to be used in different malaria vaccines and 
remains the main candidate protein for the development of 
pre-erythrocytic vaccines for the disease21.
CSP has approximately 420 amino acid residues, its 
precursor has 50-70 kDa and, later, it has been cleaved into 
surface proteins with sizes varying between 40-60 kDa22. 
In P. falciparum, the gene encoding the CSP protein is a 
single copy gene subdivided into three regions (Figure 2).
1) N-terminal region (RI), binds to heparan sulfate 
proteoglycans, which include the binding domain of 
several human HLA epitopes23. Rathore et al.20 observed 
that by deleting six amino acids from this region of the 
P. falciparum CSP, parasites were unable to bind to 
hepatocytes, preventing the sporozoite invasion process. 
Besides, it has also been shown that monoclonal antibodies 
capable of preventing the proteolytic cleavage in the 
N-terminal region of P. falciparum CSP, has the same 
effect. These data highlight the importance of this region 
in the construction of a pre-erythrocytic vaccine against 
Plasmodium.
Figure 1 - Schedule on the malaria vaccine development for approximately 50 years until 2019.
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2) Region of repetition, located in the center of the 
protein, presenting with amino acids repetitions (NANP), 
alternated by regions that are predominantly not repeated. 
In P. falciparum, this region consists of the tetrapeptide 
NANP and three variants NVDP19. This domain contains 
the majority of immunodominant B-cell epitopes for the 
production of specific antibodies to P. falciparum24 playing 
a key role in the parasites growth since experiments carried 
out removing this region led to the development of abnormal 
sporozoites with degeneration of oocysts and consequent 
death of these parasites.
3) C-terminal region: this contains a region of 
thrombospondin (TSR), also known as Region II (R II), 
anchoring glycosylphosphatidylinositol (GPI). A TSR is 
very similar to what is present in the human host, acting 
as a camouflage, delaying or giving time for the parasite 
to reproduce and respond to the host immune system, in 
addition to having the benefit of contributing to the proper 
development of sporozoites in the mosquito’s salivary 
gland25. The C-terminal region of the protein contains three 
T-cell epitopes: the first epitope is CD4+ T cell (Th2R), 
which is located before TSR, the second epitope is CD8+ 
T cell (Th3R) within the region TSR and a “promiscuous” 
CD4 T-cell epitope (CS.T3). This method is conserved 
among all parasites26. 
RTS’S vaccine clinical trials. 
A vaccine candidate, after its discovery, goes through 
elaborate stages of development until its approval as a 
commercial product. Thus, regulatory agencies around 
the world share this clinical process (in vitro tests on live 
animals) and clinical trials on humans. Clinical trials 
evaluate the safety and effectiveness of a possible candidate 
through four different stages: I, II, III and IV27.
Phase I trials evaluate the first dose of a vaccine 
administered to humans, the main objective of which 
is to test the safety, dosage, route of administration and 
effectiveness of the immune response in a small number of 
volunteers from an endemic and/ or non-endemic region for 
the disease. Phase II trials analyze a much larger population 
in its endemic setting and in multicentric locations. In this 
case, it evaluates whether the vaccine will be immunogenic 
and protective against what it was designed for. Phase II 
trials can be further divided into 1) Phase IIa, which 
provides preliminary data, through human challenge studies 
on vaccine efficiency in individuals who have never had 
the disease or who had it but are healthy in the first time 
point; 2) Phase IIb, the safety and efficiency of the vaccine 
is tested, compared to a placebo or standard vaccine used 
previously. Phase III trials, on the other hand, assess the 
incidence of the disease in vaccinated and unvaccinated 
Figure 2- Structure of P. falciparum CSP. Approximately 420 amino acid residues. A: P. falciparum CSP is subdivided into three 
regions: CSP comprises an N-terminal region containing a signal peptide sequence and Region I; a Central region containing four-
aminoacid (NANP) repeats and a B epitope; and a C-terminal region containing Region II [a thrombospondin (TSP)-like domain] 
and a canonical glycosylphosphatidylinositol (GPI) anchor additional sequence in addition to three T cell epitopes. The first epitope 
is CD4+ T cell (Th2R), which is located before the TSR, the second epitope is the CD8+ T cell (Th3R) within the TSR region 
and a “promiscuous” CD4 T cell epitope (CS.T3). B: The CSP region included in the RTS’S vaccine comprises the last 18 NANP 
repeats and C-terminus exclusive of the GPI anchor additional sequence. It contains 189 amino acids from CSP and 226 aa from 
Hepatitis B virus surface antigen (HBsAg) in RTS’S which are genetically fused to the truncated CSP and serve as protein carriers. 
The CSP fragment in RTS’S contains three known T-cell epitopes: a highly variable CD4+ T-cell epitope before the TSP-like domain 
(TH2R), a highly variable CD8+ T-cell epitope within the TSP-like domain (TH3R), and a conserved “universal” CD4 + T cell epitope 
(CS.T3) at the C-terminus.
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volunteers, attesting to the final effect of the vaccine 
formulation. This phase III can also be divided into 1) phase 
IIIa, in which the results obtained are presented to the 
Regulatory Agency for the later registration and approval 
of the product for the market; 2) Phase IIIb, changes are 
made when necessary in the vaccine for approval and 
registration with the regulatory agency. While, in phase IV, 
post-marketing surveillance studies (PMS) begin, which are 
designed to continue monitoring the product in this way, 
ensuring safety and effectiveness in the target population27.
In 1985, the Walter Reed Army Research Institute 
(WRAIR) in partnership with the company GlaxoSmithKline 
Biologicals (GSK) initiated experiments for a recombinant 
vaccine using the circumsporozoite protein (CSP), a 
tetrapeptide repeat sequence found and expressed in the 
bacterium Escherichia coli and inoculated into mice. These 
produced high concentrations of antibodies against CSP, 
when evaluated in vitro and these antibodies were able to 
block the invasion of sporozoites in human hepatocyte cells, 
highlighting the importance of CSP as a vaccine candidate21.
In 1987, new formulations of the malaria vaccine were 
developed, as well as other adjuvants that were tested 
to improve their performance. A vaccine containing the 
recombinant protein from the tetrapeptide from the CSP 
repeat region was developed and tested in mice using 
aluminum hydroxide (Alum). Two groups were evaluated: 
(1) CSP + Alum group and (2) Control group (Without 
Alum). The CSP + Alum group showed high concentrations 
of antibodies when compared to the control group 
(without Alum). This new vaccine formulation using an 
adjuvant, generated antibodies that inhibited the invasion 
of sporozoites to human hepatocytes in vitro, validating 
the CSP antigen to generate protection against the human 
malaria parasite and the importance of using adjuvant in 
the formulation as a way to perfect the vaccine18.
Human clinical trials started in 1987, using synthetic 
peptides containing P. falciparum-CSP immunodominant 
epitopes conjugated to tetanus toxoid (TT) and using 
Alum as an adjuvant; 35 healthy adults were administered 
intramuscularly with three doses in monthly intervals. The 
individuals’ sera showed reactivity of 53% and 71% against 
NANP as the concentration of these peptides increased 
when 100 and 160 mg were used, respectively. The vaccine 
was shown to be safe, with no adverse reactions, only pain 
at the inoculum site. After immunizations, three individuals 
with higher antibody titers and four control volunteers were 
challenged with P. falciparum sporozoites inoculated by 
infected mosquito bites. After the challenge, all controls 
showed the disease, while 2/3 of the vaccines did not show 
parasitemia until the eleventh day; 1/3 of those vaccinated 
did not show parasitemia or symptoms of the disease during 
the other 29 days of the observed period. This vaccine 
prototype was considered safe and stimulated the production 
of antibodies in these individuals, but with short-term 
protection, requiring new, more efficient formulations to 
help controlling malaria28.
To increase and prolong the effectiveness of the vaccine 
application, in 1988, Rutgers et al, began the tests using a 
central repeat region of the P. falciparum CSP protein, fused 
after exposure to the hepatitis B surface antigen (HBsAg) 
as a carrier matrix for major B cell epitopes29.
To improve the application of the vaccine, important T 
and B cells epitopes in the C-terminal region of the CSP 
protein were included. In 1989, Nardin et al.19 carried 
out an experiment to clone T cells taken from a human 
volunteer, who was immunized with the old native CSP 
and the recombinant CSP protein. After the challenge with 
sporozoites, immunological responses were highly specific 
for a repeat region of the CSP, the “NANPNVDPNANP” 
sequence, highlighting the importance of this region in the 
composition of a malaria vaccine.
In 1991, the CSP formulation was redesigned to contain 
19 NANP repeats and the C-terminal region (amino acids 
210-398) of the CSP antigen, along with 226 amino acids 
of the hepatitis B surface antigen (HbsAg). The current 
malaria vaccine formulation is known as RTS’S produced 
and adsorbed with alum adjuvant ( RTS’S/ Alum)30.
In 1995, one of the first phase I studies in human 
immunization was carried out using the new formulation 
of the RTS’S vaccine. The test was carried out on 
20 volunteers without malaria, 10 of whom received RTS’S/
Alum and 10 received the RTS’S/Alum/MPL vaccine. 
Both formulations proved to be safe and immunogenic, as 
they induced the production of high levels of antibodies 
in vaccinated individuals. Subsequently, volunteers were 
challenged with sporozoites. Post-challenge, all individuals 
in the RTS/ Alum group and 75% in the RTS/Alum/MPL 
group developed mild malaria. The RTS/ Alum/ MPL group 
showed higher concentrations of antibodies against CSP 
on the day of the challenge compared to individuals who 
received only RTS/ Alum, but these antibodies were not 
sufficient to generate a vaccine protection24.
In 1997, new tests were reinitiated with the RTS’S 
vaccine, only this time the CSP protein in addition to fused 
to HBsAg was expressed together with unfused HBsAg. 
This study aimed at improving the safety and efficacy of 
the vaccine using more potent adjuvants, in an attempt to 
increase the immune response of immunized individuals. 
For this, a clinical trial was carried out using three vaccine 
formulations containing RTS’S. In total, 46 individuals who 
had not been exposed to malaria, aged 18 to 45 years old 
were evaluated and received 1 mL of “Vaccine 1” (RTS’S + 
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SBAS4- Alum and MPL); 0.5 mL of “Vaccine 2” (RTS’S + 
SBAS3- Oil-in-water emulsion); and 0.5 mL of “Vaccine 3” 
(SBAS2-MPL and QS21). Only 22 immunized individuals 
and six non-immunized controls were challenged with 
mosquito bites contaminated with P. falciparum. However, 
of the seven individuals who took the three doses of 
“Vaccine 3”, six volunteers did not develop the disease. The 
researchers concluded that a recombinant vaccine based on 
the fusion of CSP with the Hepatitis B antigen (HBsAg) in 
addition to a potent adjuvant could protect adult individuals 
who have never had contact with malaria3.
From the results obtained in previous studies, Stoute et al.31 
followed-up the volunteers, this time to determine the long-
term effectiveness of the immune response in individuals 
who had been immunized with RTS’S. It was found that the 
levels of antibodies were decreasing six months after the last 
dose of the vaccine. Seven volunteers from the previous study 
agreed to participate in a new challenge six months later. In 
both challenges, all controls developed parasitemia and only 
one volunteer who received “vaccine 1” was protected in both 
challenges. In all volunteers who underwent the challenge and 
became infected, the average pre-patient period was 10.8 days 
for the control group and 13.2 days for the vaccinated one, 
and this increment was statistically significant. The research 
observed the proliferation of T cells and the production of 
interferon-γ, highlighting that the response to RTS’S was 
superior when compared to responses to HbsAg. However, 
they observed that there was no correlation between the 
immune response and protection against the disease. 
RTS’S/AS02
In 2001, another research was developed to optimize 
the dose of “Vaccine 3” using the adjuvant AS02 
(RTS’S/AS02A). For this, a controlled phase I and II study 
was carried out evaluating the number of standard doses of 
the vaccine in 41 volunteers for vaccination. The vaccine was 
shown to be safe and immunogenic in all participants. After 
the immunization stage, 41 vaccinated and 23 individuals 
without malaria (controls) were submitted to the sporozoite 
challenge. After the application of the three doses of the 
vaccine, an overall efficacy of 41% was observed, starting 
from the second dose, demonstrating a partial protection 
against the challenge with P. falciparum sporozoites32.
In 2001, a randomized clinical trial was conducted to test 
the effectiveness of the RTS’S/ AS02 vaccine on 306 semi-
immune men aged 18 to 45 years old in the Gambia. One of 
the groups received three doses of the RTS’S/AS02 vaccine 
(test group) and the other three doses of rabies vaccine 
(control group). The control group, as expected, developed 
malaria earlier than the test group, in which a strong humoral 
response against CSP was shown. In the first nine weeks, the 
effectiveness of the RTS’S/AS02 vaccine was 71%. However, 
it declined to 0% after six weeks. Finally, 158 men received 
a fourth dose of the vaccine the following year (2003) and 
were followed-up again for nine weeks. After the fourth dose, 
the vaccine was 47% effective33.
Other studies carried out with 214 Mozambican children 
using the RTS’S/ AS02 vaccine. Good results have been 
observed against the first malaria infection, and the immunity 
lasted up to six months after the third dose of the vaccine34. 
Similar results were found in this same population, in which 
the efficacy of the vaccine against clinical malaria was 33%, 
showing safety, immunogenicity over 14 months after the 
beginning of the study, however a decrease in anti-CSP 
antibodies was observed during the vaccination period35.
Recent research has shown that antibodies induced by 
the RTS’S/AS02 vaccine can interact with the complement 
system. The study was conducted from a randomized phase 
IIb clinical trial with the RTS’S/AS02 vaccine in children, 
in Mozambique. Vaccination with RTS’S/AS02 induced 
anti-CSP antibodies mainly of the IgG1 subclass. . It was 
observed that these antibodies induced by the RTS’S/
AS02 vaccine were able to fix and activate the complement 
system, through the recruitment of C1q. This discovery 
implies the elimination of the pathogen through the joint 
action of antibodies with the complement system. Besides, 
a decrease in antibodies (IgG and IgM) for complement 
fixation was observed a few months after vaccination, 
making it difficult to obtain immunological memory36.
RTS’S/AS01
Pre-clinical studies have been carried out to identify 
new adjuvant formulations for use with RTS’S to achieve 
a significant and prolonged specific immunity duration.
In 2006, a study was carried out to distinguish the best 
formulation of adjuvants for the RTS’S vaccine through 
immunizations in primates (Rhesus macaques) using 
RTS’S with four formulations of adjuvants: RTS’S/AS01B; 
RTS’S/AS02A (Standard); RTS’S/ AS05 and RTS’S/AS06. 
It was observed that among the adjuvants used, AS01B 
was the one with the highest protection index between 14th 
and 34th weeks, surpassing the AS02A standard. Thus, they 
observed that RTS’S/ AS01B was the most effective and 
superior immunogenic formulation for cellular responses, 
compared to RTS’S/ AS02A (standard)37. From March 
2009 to January 2011 a phase 3 study was carried out 
with infants aged five to 17 months and infants aged six to 
12 weeks in eight countries, in Sub-Saharan Africa. One 
year after the third dose of RTS’S/ AS01, the effectiveness 
of protection against the parasite was observed in 55.8% of 
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infants aged five to 17 months and 31.3% of infants aged 
six to 12 weeks38. The participants were followed-up for 
four years. One year after the 3rd dose, it was found that 
the vaccine was able to protect this population. However, 
after this period, the antibody serum levels against CSP 
decreased in both populations8.
In 2019, the most recent phase 3 study with the RTS’S/
AS01 vaccine was carried out with a population of 109 infants 
aged six to 12 weeks and 86 infants aged 5 to 17 months. Data 
from this clinical trial found that vaccination with RTS’S/
AS01 generated antibodies predominantly of the subclasses 
IgG1 or IgG3, with lower levels of IgG2 and IgG4. There 
were associations with the protection of IgG3 antibodies 
to selected antigens, followed by the IgG1 subclass. The 
research has also highlighted the importance of these 
antibodies for improving the RTS’S/AS01 vaccine39. 
The RTS’S vaccine during phase 3 trials showed adverse 
reactions that were considered tolerable and similar to those 
of other childhood vaccines. Reported side effects were pain 
and swelling at the injection site and fever6. 
During this phase there were more reports of meningitis 
cases in children who received the vaccine, but no association 
was proven. Thus, EMA concluded that there is not enough 
information to classify the finding as a potential risk, 
reasoning that it was probably an occasional finding, but 
should be monitored during the introduction of the vaccine5,7.
Despite reports of adverse effects, reduced duration 
and low efficacy, RTS’S is the first malaria vaccine that 
has proven to be effective, as it contributes to the reduction 
of severe malaria rates and hospitalizations in children 
aged five to 17 months, which is the most affected group 
by this disease38. Among the three communities in which 
the vaccine is being implemented (Malawi, Kenya, and 
Ghana), Malawi welcomed the malaria vaccine. Therefore, 
the distribution of RTS’S malaria vaccine, even with partial 
protection, is believed to lead to a significant impact on the 
health of African children6,7.
Nowadays, the malaria vaccine is in phase 4 clinical trial 
expected to be completed in 2023. At this stage, additional 
information on the vaccine’s effectiveness and side effects 
associated with the routine use will be gathered. In 2019, the 
MVIP, WHO and Gavi - The Vaccine Alliance, committed to 
additional funding to complete the pilot program by 20236 .
CONCLUSION AND PERSPECTIVES
Therefore, both the RTS’S vaccine using adjuvant AS01 
and AS02 have points to be improved. Although the reason 
for this partial generation of protection is not yet clear, the 
research previously cited indicates that the polymorphism 
in the central and C-terminal regions, as well as the 
particularity of each adjuvant and the age of the vaccines 
are factors that influence their effectiveness. 
Other obstacles still have to be overcome for the 
development of an effective vaccine against malaria, such as 
the genetic diversity present in the Central repeating regions 
and the C-terminal of P falciparum CSP that makes up the 
RTS’S/ AS01 vaccine. These polymorphic regions make 
it difficult to obtain immunological memory, a limitation 
that has been observed in clinical studies in different areas 
endemic for malaria40. 
The C-terminal region of the protein has polymorphisms 
concentrated in the Th2R and Th3R regions, while the 
central repeat region of the CSP antigen, has polymorphisms 
in the NANP and NVDP repeat sequences. These data 
were retrieved from different geographic areas, mainly 
in African, Asian and Ocean continents41. These types 
of studies underscore the importance of incorporating 
population genetic studies into the future malaria vaccine 
project, and it is considered revealing to include the 
assessment of the diversity of Pf CSP C-terminal in the 
malaria vaccine implementation program and to further 
improve the understanding of how genetic diversity affects 
the effectiveness of the RTS’S/ AS01 vaccine42.
Currently, through simulations, researchers have been 
finding other ways to deal with Plasmodium, one of which 
is to associate the vaccine with anti-malarial drugs. This new 
alternative has a great potential for impact on endemic regions 
since the combination of the vaccine-drug combination 
will decrease the prevalence of resurgence of transmission 
after the end of vaccination. The joint action of vaccines 
and medicines reduces the number of rounds and years of 
intervention to achieve the same impact on public health as 
chemoprevention, in addition to no age differentiation43.
More research is needed to ensure the development of an 
effective vaccine against the malaria parasite, contributing 
to a longer-lasting, safe immunological memory for all age 
groups and a long-term control and possible eradication 
of malaria. The use of other proteins as immunogenic as 
CSP can be a new way of experimenting to create a safer 
formulation of a multivalent vaccine. The importance 
of analyzing new adjuvants for the composition of these 
vaccines, such as liposomes and Bacillus subtilis spores 
which showed promising results for other antigens, but 
still need further evaluation in animal and human models 
is also noteworthy.
ACKNOWLEDGMENTS
We would like to thank the FIOCRUZ support 
Foundation - Fiotec, the Postgraduate Program in Cellular 
and Molecular Biology-PGBCM of Instituto Oswaldo Cruz-
Almeida et al.
Rev Inst Med Trop São Paulo. 2021;63:e11Page 8 of 9
IOC / FIOCRUZ, and Leonidas and Maria Deane Institute 
- ILMD / Fiocruz Amazonia for funding the scholarship.
CONFLICT OF INTERESTS
The authors state no conflicts of interest.
REFERENCES
 1. World Health Organization. World malaria report 2019. Geneva: 
WHO; 2019.
 2. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline 
Adjuvant Systems in vaccines: concepts, achievements and 
perspectives. Expert Rev Vaccines. 2007;6:723-39.
 3. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, 
Desmons P, et al. A preliminary evaluation of a recombinant 
circumsporozoite protein vaccine against Plasmodium 
falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. 
N Engl J Med. 1997;336:86-91. 
 4. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, 
et al. Efficacy of RTS,S/AS01E vaccine against malaria in 
children 5 to 17 months of age. N Engl J Med. 2008;359:2521-
32. 
 5.  European Medicines Agency. First malaria vaccine receives 
positive scientific opinion from EMA: press release 24/07/2015. 
[cited 2020 Oct 21]. Available from: http://www.ema.europa.
eu/en/news/first-malaria-vaccine-receives-positive-scientific-
opinion-ema
 6.  World Health Organization. Q&A on the malaria vaccine 
implementation programme (MVIP): march 2020. [cited 2020 
Oct 21]. Available from: http://www.who.int/malaria/media/
malaria-vaccine-implementation-qa/en/
 7.  World Health Organization. First malaria vaccine: a potential new 
tool for child health and improved malaria control. [cited 2020 
Oct 21]. Available from: https://www.who.int/publications/i/
item/who-cds-gmp-2018-05
 8.  The RTS,S Clinical Trials Partnership. Efficacy and safety 
of the RTS,S/AS01 malaria vaccine during 18 months 
after vaccination: a phase 3 randomized, controlled trial in 
children and young infants at 11 African sites. PLoS Med. 
2014;11:e1001685.
 9. Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon 
C, Garçon N. Adjuvant system AS01: helping to overcome 
the challenges of modern vaccines. Expert Rev Vaccines. 
2017;16:55-63.
 10. Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil 
CR, Recchia J, et al. Induction of cross-reactive cytotoxic 
T-lymphocyte responses specific for HIV-1 gp120 using 
saponin adjuvant (QS-21) supplemented subunit vaccine 
formulations. Vaccine. 1997;15:1001-7.
 11. Ramon G. Procédés pour accroître la production de antitoxines. 
Ann Inst Pasteur. 1926;40:1-10.
 12. Glenny AT, Buttle GA, Stevens MF. Rate of disappearance of 
diphtheria toxoid injected into rabbits and guinea-pigs: toxoid 
precipitated with alum. J Pathol Bacteriol. 1931;34:267-75. 
 13. Brewer JM. (How) do aluminium adjuvants work/Immunol Lett. 
2006;102:10-5.
 14. Freund J, Sommer HE, Walter AW. Immunization against malaria: 
vaccination of ducks with killed parasites incorporated with 
adjuvants. Science. 1945; 102:200-2. 
 15. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective 
immunity produced by the injection of x-irradiated sporozoites 
of Plasmodium berghei. Nature. 1967;216:160-2. 
 16. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. 
Preliminary studies on vaccination of Rhesus monkeys 
with irradiated sporozoites of Plasmodium knowlesi and 
characterization of surface antigens of these parasites. Bull 
World Health Organ. 1979;57 Suppl 1:165-73. 
 17. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization 
of man against sporozite-induced falciparum malaria. Am J 
Med Sci. 1973; 266:169-77. 
 18. Hollingdale MR, Ballou WR, Aley SB, Young JF, Pancake 
S, Miller LH, et al. Plasmodium falciparum: elicitation by 
peptides and recombinant circumsporozoite proteins of 
circulating mouse antibodies inhibiting sporozoite invasion 
of hepatoma cells. Exp Parasitol. 1987;63:345-51. 
 19. Nardin EH, Herrington DA, Davis J, Levine M, Stuber D, 
Takacs B, et al. Conserved repetitive epitope recognized by 
CD4+ clones from a malaria-immunized volunteer. Science. 
1989;246:1603-6.
 20. Rathore D, Sacci JB, de la Vega P, McCutchan TF. Binding 
and invasion of liver cells by Plasmodium falciparum 
sporozoites: essential involvement of the amino terminus of 
circumsporozoite protein. J Biol Chem. 2002;277:7092-8.
 21. Young JF, Hockmeye WT, Gross M, Ballou WR, Wirtz RA, 
Trosper JH, et al. Expression of Plasmodium falciparum 
circumsporozoite proteins in Escherichia coli for potential use 
in a human malaria vaccine. Science. 1985;228:958-62. 
 22. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium 
circumsporozoite protein is proteolytically processed during 
cell invasion. J Exp Med. 2005;201:27-33. 
 23. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney 
J, Chesnut RW, et al. Degenerate cytotoxic T cell epitopes 
from P. falciparum restricted by multiple HLA-A and HLA-B 
supertype alleles. Immunity. 1997;7:97-112.
 24. Gordon DM, McGovern TW, Krzych U, JC Cohen, Schneider 
I, LaChance R, et al. Safety, immunogenicity, and efficacy 
of a recombinantly produced Plasmodium falciparum 
circumsporozoite protein-hepatitis B surface antigen subunit 
vaccine. J Infect Dis. 1995;171:1576-85. 
 25. Doud MB, Koksal AC, Mi LZ, Song G, Lu C, Springer TA. 
Unexpected fold in the circumsporozoite protein target of 
Rev Inst Med Trop São Paulo. 2021;63:e11
Circumsporozoite Surface Protein-based malaria vaccines: a review
Page 9 of 9
malaria vaccines. Proc Natl Acad Sci USA. 2012;109:7817-22. 
 26. Kaslow DC, Biernaux S. RTS’S: toward a first landmark on the 
malaria vaccine technology roadmap. Vaccine. 2015;33:7425-32. 
 27. Singh K, Mehta S. The clinical development process for a novel 
preventive vaccine: an overview. J Postgrad Med. 2016;62:4-11.
 28. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, 
Davis J, et al. Safety and immunogenicity in man of a synthetic 
peptide malaria vaccine against Plasmodium falciparum 
sporozoites. Nature. 1987;328:257-9. 
 29. Rutgers T, Gordon D, Gathoye AM, Hollingdale M, Hockmeyer 
WT, Rosenberg M, et al. Hepatitis B surface antigen as a carrier 
matrix for the repetitive epitope of the circumsporozoite protein 
of Plasmodium falciparum. Bio/Technology. 1988;6:1065-70. 
 30. Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen 
JH. Phase I clinical trial of a recombinant malaria vaccine 
consisting of the circumsporozoite repeat region of Plasmodium 
falciparum coupled to hepatitis B surface antigen. Am J Trop 
Med Hyg. 1991;45:533-8.
 31. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, 
et al. Long-term efficacy and immune responses following 
immunization with the RTS,S malaria vaccine. J Infect Dis. 
1998;178:1139-44.
 32. Kester KE, McKinney DA, Tornieporth N, Ockenhouse 
CF, Heppner DG, Hall T, et al. Efficacy of recombinant 
circumsporozoite protein vaccine regimens against 
experimental Plasmodium falciparum malaria. J Infect Dis. 
2001;183:640-7.
 33. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, 
Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine 
against Plasmodium falciparum infection in semi-immune 
adult men in The Gambia: a randomised trial. Lancet. 
2001;358:1927-34.
 34. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi 
C, et al. Safety and immunogenicity of RTS,S/AS02D malaria 
vaccine in infants. N Engl J Med. 2008;359:2533-44.
 35. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, 
Mandomando I, et al. Safety, immunogenicity and duration of 
protection of the RTS,S/AS02(D) malaria vaccine: one year 
follow-up of a randomized controlled phase I/IIb trial. PLoS 
One. 2010;5:e13838.
 36. Kurtovic L, Boyle MJ, Opi DH, Kennedy AT, Tham WH, Reiling 
L, et al. Complement in malaria immunity and vaccines. 
Immunol Rev. 2020;293:38-56.
 37. Stewart VA, Walsh DS, McGrath SM, Kester KE, Cummings JF, 
Voss G, et al. Cutaneous delayed-type hypersensitivity (DTH) 
in a multi-formulation comparator trial of the anti-falciparum 
malaria vaccine candidate RTS,S in Rhesus macaques. Vaccine. 
2006;24:6493-502.
 38. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/
AS01 malaria vaccine with or without a booster dose in infants 
and children in Africa: final results of a phase 3, individually 
randomised, controlled trial. Lancet. 2015;386:31-45. 
 39. Dobaño C, Ubillos I, Jairoce C, Gyan B, Vidal M, Jiménez A, et al. 
RTS,S/AS01E immunization increases antibody responses to 
vaccine-unrelated Plasmodium falciparum antigens associated 
with protection against clinical malaria in African children: a 
case-control study. BMC Med. 2019;17:157.
 40. Zeeshan M, Alam MT, Vinayak S, Bora H, Tyagi RK, Alam 
MS, et al. Genetic variation in the Plasmodium falciparum 
circumsporozoite protein in India and its relevance to RTS,S 
malaria vaccine. PLoS One. 2012;7:e43430. 
 41. Lê HG, Kang JM, Moe M, Jun H, Thái TL, Lee J, et al. Genetic 
polymorphism and natural selection of circumsporozoite 
surface protein in Plasmodium falciparum field isolates from 
Myanmar. Malar J. 2018;17:361.
 42. Mohamed NS, Ali Albsheer MM, Abdelbagi H, Siddig EE, 
Mohamed MA, Ahmed AE, et al. Genetic polymorphism of 
the N-terminal region in circumsporozoite surface protein of 
Plasmodium falciparum field isolates from Sudan. Malar J. 
2019;18:333. 
 43. Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass 
campaigns combining antimalarial drugs and anti-infective 
vaccines as seasonal interventions for malaria control, 
elimination and prevention of resurgence: a modelling study. 
BMC Infect Dis. 2019;19:920.
